Product Data Sheet

Product Name: SBP-1750
Cat. No.: GC78994

Chemical Properties

Cas. No.	1884219-70-8		
Formula	$C_{21}H_{22}ClN_5O_4$	M.Wt	443.88
Solubility		Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure			



Background

SBP-1750 is an orally active ULK inhibitor and an ATG13 degrader. SBP-1750 strongly inhibits ULK1/2 activity, with IC_{50} values of 8 and 50 nM, respectively. SBP-1750 induces ATG13 degradation, with an EC 50 value of 114 nM. SBP-1750 can inhibit autophagy in cancer cells and induce cell death. SBP-1750 can be used in cancer research, such as for pancreatic cancer [1].

In Vivo, SBP-1750 (40 mg/kg; i.g.; daily; from day 10 to 28) reduces pancreatic tumor size and metastasis in KPC4662 PDAC mice model[1].

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

In Vitro, SBP-1750 (5 μM; 18 hours) inhibits autophagy in A549 cells [1]. SBP-1750 (48 h) induces ATG13 degradation in A549 ATG13-HiBiT cells with EC50 of 114 nM[1]. SBP-1750 (48 h) inhibits cell viability in KRAS-mutant cancer cells (A549, MiaPaCa2, NCI-H358, PANC-1) with IC_{50} <50 nM[1].

References:

[1]. Hagan PM, et al. ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers. bioRxiv [Preprint]. 2025 Oct 15:2025.10.14.682402.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA